Literature DB >> 19342860

Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study.

Soon Young Lee1, Kwang Jae Lee, Soo Jeong Kim, Sung Won Cho.   

Abstract

BACKGROUND/AIMS: People may have symptoms of multiple disorders at the same time. We aimed to determine prevalence and risk factors for overlaps between gastroesophageal reflux disease (GERD), dyspepsia and irritable bowel syndrome (IBS) in a Korean population.
METHODS: A cross-sectional survey was performed on 1,688 randomly selected Korean subjects. Data on 1,443 subjects could be analyzed. Dyspepsia and IBS were diagnosed using modified Rome II criteria.
RESULTS: The prevalences of GERD, dyspepsia and IBS were 8.5, 9.5 and 9.6%. Overlaps between GERD and dyspepsia, GERD and IBS, and dyspepsia and IBS were observed in 2.3 (95% CI 1.4-3.0), 2.0 (95% CI 1.2-2.6%) and 1.3% (95% CI 0.6-1.8%) of the population. 27 and 24% of GERD subjects suffered from dyspepsia and IBS. 24 and 14% of dyspeptic subjects had GERD and IBS. 21 and 14% of IBS subjects had GERD and dyspepsia. Anxiety was significantly associated with GERD overlap (OR 2.73, 95% CI 1.13-6.57), dyspepsia overlap (OR 3.19, 95% CI 1.33-7.63) and IBS overlap (OR 4.92, 95% CI 2.04-11.84), compared with GERD alone, dyspepsia alone and IBS alone.
CONCLUSIONS: Overlaps between GERD, dyspepsia, and IBS are common in the general population. These overlaps occur predominantly in individuals with anxiety.

Entities:  

Mesh:

Year:  2009        PMID: 19342860     DOI: 10.1159/000211715

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  57 in total

1.  Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests.

Authors:  Su Youn Nam; Byung Chang Kim; Kum Hei Ryu; Bum Joon Park
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

Review 2.  Functional heartburn: definition and management strategies.

Authors:  Frank Zerbib; Stanislas Bruley des Varannes; Mireille Simon; Jean Paul Galmiche
Journal:  Curr Gastroenterol Rep       Date:  2012-06

Review 3.  Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome.

Authors:  Nicola de Bortoli; Irene Martinucci; Massimo Bellini; Edoardo Savarino; Vincenzo Savarino; Corrado Blandizzi; Santino Marchi
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 4.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

5.  Prevalence and risk factors of irritable bowel syndrome in Asia.

Authors:  Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

6.  Asian motility studies in irritable bowel syndrome.

Authors:  Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

7.  The Overlap Between GERD and Functional Bowel Disorders - When East Meets Rome.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

8.  Analysis of the gastrointestinal symptoms of uninvestigated dyspepsia and irritable bowel syndrome.

Authors:  Kazutoshi Hori; Takayuki Matsumoto; Hiroto Miwa
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

9.  Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria.

Authors:  Young Wook Noh; Hye-Kyung Jung; Seong-Eun Kim; Sung-Ae Jung
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

10.  Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes.

Authors:  Ami D Sperber; Roy Dekel
Journal:  J Neurogastroenterol Motil       Date:  2010-04-27       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.